Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia
Open Access
- 22 August 2006
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 3 (8), e327
- https://doi.org/10.1371/journal.pmed.0030327
Abstract
The identification of schizophrenia biomarkers is a crucial step towards improving current diagnosis, developing new presymptomatic treatments, identifying high-risk individuals and disease subgroups, and assessing the efficacy of preventative interventions at a rate that is not currently possible. 1H nuclear magnetic resonance spectroscopy in conjunction with computerized pattern recognition analysis were employed to investigate metabolic profiles of a total of 152 cerebrospinal fluid (CSF) samples from drug-naïve or minimally treated patients with first-onset paranoid schizophrenia (referred to as “schizophrenia” in the following text) and healthy controls. Partial least square discriminant analysis showed a highly significant separation of patients with first-onset schizophrenia away from healthy controls. Short-term treatment with antipsychotic medication resulted in a normalization of the disease signature in over half the patients, well before overt clinical improvement. No normalization was observed in patients in which treatment had not been initiated at first presentation, providing the first molecular evidence for the importance of early intervention for psychotic disorders. Furthermore, the alterations identified in drug-naïve patients could be validated in a test sample set achieving a sensitivity and specificity of 82% and 85%, respectively. Our findings suggest brain-specific alterations in glucoregulatory processes in the CSF of drug-naïve patients with first-onset schizophrenia, implying that these abnormalities are intrinsic to the disease, rather than a side effect of antipsychotic medication. Short-term treatment with atypical antipsychotic medication resulted in a normalization of the CSF disease signature in half the patients well before a clinical improvement would be expected. Furthermore, our results suggest that the initiation of antipsychotic treatment during a first psychotic episode may influence treatment response and/or outcome.Keywords
This publication has 42 references indexed in Scilit:
- Metabolic Characterization of the R6/2 Transgenic Mouse Model of Huntington's Disease by High-Resolution MAS1H NMR SpectroscopyJournal of Proteome Research, 2006
- Metabolic characterization of distinct neuroanatomical regions in rats by magic angle spinning 1H nuclear magnetic resonance spectroscopyMagnetic Resonance in Medicine, 2005
- Cerebrospinal fluid from patients with dementia contains increased amounts of an unknown factorJournal of Neuroscience Research, 2004
- Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stressMolecular Psychiatry, 2004
- Post-mortem evidence from human brain tissue of disturbed glucose metabolism in mood and psychotic disordersMolecular Psychiatry, 2004
- 1H magnetic resonance spectroscopy in human hydrocephalusJournal of Magnetic Resonance Imaging, 2003
- Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With SchizophreniaAmerican Journal of Psychiatry, 2003
- Metabolic changes in the cerebrospinal fluid of patients with lumbar disc herniation or spinal stenosisJournal of Neuroscience Research, 2002
- Metabonomics: a platform for studying drug toxicity and gene functionNature Reviews Drug Discovery, 2002
- 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic dataXenobiotica, 1999